Form 4: Quest Diagnostics Exec Sells Shares After Option Exercise
Statement of Changes in Beneficial Ownership (Form 4)
Quest Diagnostics SVP & General Counsel Michael E. Prevoznik exercised stock options and sold a portion of the acquired common stock under a Rule 10b5-1 plan.
Summary
- Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics Inc. (DGX), reported transactions on September 26, 2025.
- Exercised 227 Non-Qualified Stock Options at an exercise price of $103.57 per share.
- Sold 83 shares of Common Stock at a weighted average price of $187.2198 per share, with trades ranging from $187.00 to $187.480.
- Sold an additional 144 shares of Common Stock at a weighted average price of $188.6581 per share, with trades ranging from $188.220 to $189.080.
- All reported transactions were executed pursuant to a pre-arranged Rule 10b5-1 sales plan.
- Following these transactions, Michael E. Prevoznik directly beneficially owns 38,117 shares of Common Stock.
- Additionally, 5,692 shares are indirectly beneficially owned through the Company's 401(k)/Supplemental Deferred Compensation Plan.
Sentiment
Score: 6
Explanation: A routine insider transaction involving the exercise of vested stock options and subsequent sale of a portion of the shares under a pre-arranged 10b5-1 plan. This is a common practice for executives to manage their equity compensation and is generally viewed as neutral to slightly positive as it indicates the executive is monetizing their compensation at current market prices.
Positives
- The executive is monetizing vested equity compensation, which is a common and routine practice.
- Transactions were conducted under a Rule 10b5-1 plan, indicating pre-planning and not a reaction to immediate market conditions.
Negatives
- Insider selling, even if planned, can sometimes be perceived negatively by the market, though this is a routine transaction for executive compensation.
Risks
- No new specific risks to the company are identified in this Form 4 filing, which primarily reports executive stock transactions.
Industry Context
This filing is a routine disclosure of an executive's personal stock transactions and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine, pre-planned executive compensation transaction and does not reflect a change in company fundamentals or strategy.
Key Dates
| Date | Description |
|---|---|
| 02/19/2019 | First installment of Non-Qualified Stock Options vested. |
| 02/19/2020 | Second installment of Non-Qualified Stock Options vested. |
| 02/19/2021 | Final installment of Non-Qualified Stock Options vested. |
| 09/26/2025 | Date of option exercise and subsequent sale of common stock. |
| 09/30/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
| 02/19/2028 | Expiration date of the Non-Qualified Stock Options. |
Keywords
Quest Diagnostics, DGX, Form 4, Insider Trading, Stock Options, Executive Compensation, Michael E. Prevoznik, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.